Last checked at 8 Feb 2013 16:45
Port Erin Biopharma Investments Limited
Replacement - Director's Dealing
The following amendment has been made to the 'Director's Dealing' announcement released on 30 January 2013 at 9:55am under RNS No 6844W.
Jim Mellon has a beneficial interest in 5,016,000 Ordinary Shares representing 15.2% of the issued ordinary share capital of the Company, not 4,175,000 Ordinary Shares as the previous announcement stated.
All other details remain unchanged.
The full amended text is shown below.
Port Erin Biopharma Investments Limited
("Port Erin" or the "Company")
Director's Dealing
Port Erin, the AIM listed company focused on investing in the biotechnology and biopharmaceutical sectors, was informed that the Chairman, Jim Mellon, purchased 575,000 Ordinary Shares at an average price of 6.26 pence per share on 29th January 2013.
Following this transaction, the total Ordinary Shares in which Jim Mellon has a beneficial interest is 5,016,000 representing 15.2% of the issued ordinary share capital of the Company.
Enquiries:
| |||
Port Erin Biopharma Investments Limited |
| ||
Denham Eke | (+44) 1624 639396 | ||
|
| ||
Libertas Capital Corporate Finance Limited |
| ||
Sandy Jamieson | (+44) 20 7569 9650 | ||
|
| ||
Rivington Street Corporate Finance Limited |
| ||
John Levinson | (+44) 20 7562 3350 | ||